MeiraGTx Announces Investigational Gene Therapy Continues to Demonstrate Statistically Significant Improvement in Vision in Patients with X-Linked Retinitis Pigmentosa One Year After Treatment
November 13, 2020 17:55 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced 12-month data from the...
MeiraGTx to Present at the Barclays Gene Editing & Gene Therapy Summit
November 10, 2020 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria...
MeiraGTx Reports Third Quarter 2020 Financial Results
November 05, 2020 08:30 ET
|
MeiraGTx
MeiraGTx preparing to initiate Phase 3 trial of AAV-RPGRPlasmid production facility expected to be completed year-end 2020 LONDON and NEW YORK,, Nov. 05, 2020 (GLOBE NEWSWIRE) --...
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at AAO 2020 Virtual Meeting
October 28, 2020 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that twelve-month...
MeiraGTx Announces Nine-Month Data from Phase 1/2 Trial of AAV-RPGR Demonstrating Significant and Sustained Vision Improvement in X-Linked Retinitis Pigmentosa (XLRP)
October 03, 2020 10:50 ET
|
MeiraGTx
Data presented at EURETINA 2020 Virtual Congress show sustained improvements in retinal sensitivity at nine monthsSignificant improvements were also demonstrated in the time taken to walk through a...
MeiraGTx to Present at the Chardan 4th Annual Genetic Medicines Conference
September 28, 2020 16:30 ET
|
MeiraGTx
LONDON and NEW YORK, Sept. 28, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes,...
MeiraGTx Announces Data from Ongoing Clinical Trial of AAV-RPGR for the Treatment of X-Linked Retinitis Pigmentosa to be Presented at EURETINA 2020 Virtual Meeting
September 22, 2020 08:30 ET
|
MeiraGTx
LONDON and NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced nine-month...
MeiraGTx Reports Second Quarter 2020 Financial Results
August 06, 2020 08:00 ET
|
MeiraGTx
- Positive initial data from Phase 1/2 clinical trial of AAV-RPGR for the treatment of XLRP recently presented- AAV-RPGR to advance into Phase 3 Lumeos clinical trial- Expands manufacturing...
MeiraGTx Expands Leadership Team with Appointment of Robert K. Zeldin, M.D. as Chief Medical Officer
August 05, 2020 08:30 ET
|
MeiraGTx
LONDON and NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment...
MeiraGTx Announces Positive Clinical Data Demonstrating Treatment with AAV-RPGR Investigational Gene Therapy Improves Vision in X-Linked Retinitis Pigmentosa Patients
July 17, 2020 07:30 ET
|
MeiraGTx
• Data being presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting • Significant improvements demonstrated after treatment in Phase 1/2 clinical trial • Based...